Colombo R - Search Results

1

Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase.

Perrera C, Colombo R, Valsasina B, Carpinelli P, Troiani S, Modugno M, Gianellini L, Cappella P, Isacchi A, Moll J, Rusconi L. Perrera C, et al. Among authors: colombo r. J Biol Chem. 2010 Apr 16;285(16):11775-85. doi: 10.1074/jbc.M109.068312. Epub 2010 Feb 22. J Biol Chem. 2010. PMID: 20177074 Free PMC article.

2

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.

Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A, Moll J. Modugno M, et al. Among authors: colombo r. Cancer Res. 2007 Sep 1;67(17):7987-90. doi: 10.1158/0008-5472.CAN-07-1825. Cancer Res. 2007. PMID: 17804707

3

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH. Gontarewicz A, et al. Among authors: colombo r. Blood. 2008 Apr 15;111(8):4355-64. doi: 10.1182/blood-2007-09-113175. Epub 2008 Feb 11. Blood. 2008. PMID: 18268096 Free article.

4

Target validation to biomarker development: focus on RNA interference.

Colombo R, Moll J. Colombo R, et al. Mol Diagn Ther. 2008;12(2):63-70. doi: 10.1007/BF03256271. Mol Diagn Ther. 2008. PMID: 18422370 Review.

5

Target validation and biomarker identification in oncology : the example of aurora kinases.

Colombo R, Moll J. Colombo R, et al. Mol Diagn Ther. 2008;12(2):71-6. doi: 10.1007/BF03256272. Mol Diagn Ther. 2008. PMID: 18422371 Review.

6

Destabilizing aneuploidy by targeting cell cycle and mitotic checkpoint proteins in cancer cells.

Colombo R, Moll J. Colombo R, et al. Curr Drug Targets. 2010 Oct;11(10):1325-35. doi: 10.2174/1389450111007011325. Curr Drug Targets. 2010. PMID: 20840075 Review.

7

Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.

Colombo R, Caldarelli M, Mennecozzi M, Giorgini ML, Sola F, Cappella P, Perrera C, Depaolini SR, Rusconi L, Cucchi U, Avanzi N, Bertrand JA, Bossi RT, Pesenti E, Galvani A, Isacchi A, Colotta F, Donati D, Moll J. Colombo R, et al. Cancer Res. 2010 Dec 15;70(24):10255-64. doi: 10.1158/0008-5472.CAN-10-2101. Cancer Res. 2010. PMID: 21159646

8

Targeting aneuploid cancer cells.

Colombo R, Moll J. Colombo R, et al. Expert Opin Ther Targets. 2011 May;15(5):595-608. doi: 10.1517/14728222.2011.558007. Epub 2011 Feb 12. Expert Opin Ther Targets. 2011. PMID: 21314491 Review.

9

Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors.

Caldarelli M, Angiolini M, Disingrini T, Donati D, Guanci M, Nuvoloni S, Posteri H, Quartieri F, Silvagni M, Colombo R. Caldarelli M, et al. Among authors: colombo r. Bioorg Med Chem Lett. 2011 Aug 1;21(15):4507-11. doi: 10.1016/j.bmcl.2011.05.122. Epub 2011 Jun 14. Bioorg Med Chem Lett. 2011. PMID: 21723120

10

Selective inhibition of pancreatic ductal adenocarcinoma cell growth by the mitotic MPS1 kinase inhibitor NMS-P715.

Slee RB, Grimes BR, Bansal R, Gore J, Blackburn C, Brown L, Gasaway R, Jeong J, Victorino J, March KL, Colombo R, Herbert BS, Korc M. Slee RB, et al. Among authors: colombo r. Mol Cancer Ther. 2014 Feb;13(2):307-315. doi: 10.1158/1535-7163.MCT-13-0324. Epub 2013 Nov 26. Mol Cancer Ther. 2014. PMID: 24282275 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,061 results

Search Page